An open label study of the safety and efficacy of a single dose of weekly chloroquine and azithromycin administered for malaria prophylaxis in healthy adults challenged with 7G8 chloroquine-resistant Plasmodium falciparum in a controlled human malaria infection model

Table 3 Characteristics of CQAZ group based on protection from malaria parasitemia

Variable	Protected (N = 5)	Not protected (N = 7)	All subjects (N = 12)
Age
n	5	7	12
Mean	27.4	33.7	31.8
Median	31.0	33.0	31.5
Min, max	21, 33	21, 43	21, 43
Two sample t-test	0.1102
Gender: n (%)
Male	4 (80.0%)	4 (57.1%)	8 (66.7%)
Female	1 (20.0%)	3 (42.9%)	4 (33.3%)
Fisher’s exact test	0.5758
Body mass index
Mean	26.7	30.4	31.1
Median	23.4	29.5	25.3
Two sample t-test	0.4274
Ethnicity: n (%)
Hispanic or latino	0	1 (14.2%)	1 (8.3%)
Not hispanic or latino	5 (100.0%)	6 (85.7%)	11 (91.6%)
Fisher’s exact test	> 0.9999
Race: n (%)
American Indian or Alaska Native	0	0	0
Asian	0	1 (14.2%)	1 (8.3%)
Black of African American	2 (40.0%)	2 (28.5%)	4 (33.3%)
Native Hawaiian or Other Islander	0	0	0
White	3 (60.0%)	4 (57.1%)	7 (58.3%)
Other	0	0	0
Multi-racial	0	0	0
Fisher’s exact test	0.8674

Protected group represent CQAZ enrolled subjects that did not have symptomatic parasitemia during post-exposure prophylaxis dosing or a positive smear after dosing completed. The Not Protected group represents CQAZ enrolled subjects with either symptomatic parasitemia during the post-exposure dosing (n = 1) or a positive smear after dosing was completed (n = 6)

ISSN: 1475-2875